MCID: HMT018
MIFTS: 59

Hematopoietic Stem Cell Transplantation

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Hematopoietic Stem Cell Transplantation

MalaCards integrated aliases for Hematopoietic Stem Cell Transplantation:

Name: Hematopoietic Stem Cell Transplantation 39 60

Characteristics:

Orphanet epidemiological data:

60
hematopoietic stem cell transplantation
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

ICD10 via Orphanet 35 Z94.8
Orphanet 60 ORPHA90053

Summaries for Hematopoietic Stem Cell Transplantation

MalaCards based summary : Hematopoietic Stem Cell Transplantation is related to post-transplant lymphoproliferative disease and immunodysregulation, polyendocrinopathy, and enteropathy, x-linked. An important gene associated with Hematopoietic Stem Cell Transplantation is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Hydroxocobalamin and Ferrous succinate have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 77 Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem... more...

Related Diseases for Hematopoietic Stem Cell Transplantation

Diseases related to Hematopoietic Stem Cell Transplantation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 post-transplant lymphoproliferative disease 32.6 IL10 IL6 TNF
2 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.6 IFNG IL10 IL2
3 aspergillosis 32.6 CLEC7A IFNG IL10 TNF
4 chronic active epstein-barr virus infection 32.2 CTLA4 IFNG IL10 IL2
5 chronic graft versus host disease 31.4 IFNG IL10 TNF
6 pneumonia 31.1 IL10 IL6 TNF
7 hemophagocytic lymphohistiocytosis 31.1 IFNG IL10 TNF
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.1 CTLA4 IFNG IL10
9 acute graft versus host disease 31.0 ARHGAP45 IFNG IL10 IL2 TNF
10 bronchiolitis 30.9 IFNG IL10 IL6 TNF
11 bronchiolitis obliterans 30.9 IFNG IL10 IL6 TNF
12 relapsing-remitting multiple sclerosis 30.6 IFNG IL10 TNF
13 candidiasis 30.5 CLEC7A IFNG IL10
14 cytomegalovirus infection 30.5 HLA-A HLA-B HLA-E IL6 TNF
15 leishmaniasis 30.5 IFNG IL10 TNF
16 omenn syndrome 30.5 IFNG IL10 TNF
17 toxoplasmosis 30.5 IFNG IL10 IL6 TNF
18 demyelinating disease 30.4 IFNG IL10 TNF
19 gastroenteritis 30.4 IL10 IL6 TNF
20 cytomegalovirus retinitis 30.4 HLA-A HLA-B IFNG TNF
21 trichosporonosis 30.3 IFNG TNF
22 bacterial infectious disease 30.3 IFNG IL10 IL6 TNF
23 aplastic anemia 30.3 HLA-A HLA-B IFNG IL2 IL6 TNF
24 arthritis 30.3 IFNG IL10 IL6 TNF
25 bacterial meningitis 30.3 IL10 IL6 TNF
26 autoimmune disease 30.2 CTLA4 IFNG IL10 IL2 IL6 TNF
27 rheumatic disease 30.2 HLA-B IFNG IL10 TNF
28 graft-versus-host disease 30.1 ARHGAP45 HLA-A HLA-B HLA-C IFNG IL10
29 mycobacterium tuberculosis 1 30.1 IFNG IL10 TNF
30 multiple sclerosis 30.1 CTLA4 IFNG IL10 IL2 IL6 TNF
31 tetanus 30.1 IFNG IL10 IL2
32 large granular lymphocyte leukemia 30.1 IFNG KIR2DL3
33 sezary's disease 30.1 CTLA4 IFNG IL2 KIR3DL1
34 pertussis 30.0 IL10 IL6 TNF
35 crohn's colitis 30.0 IFNG IL2 TNF
36 meningitis 30.0 IFNG IL10 IL6 TNF
37 myocarditis 30.0 HLA-B IL6 TNF
38 cerebrovascular disease 30.0 IL6 MTHFR TNF
39 visceral leishmaniasis 29.9 IFNG IL10 IL2 TNF
40 sarcoidosis 1 29.9 IFNG IL2 TNF
41 herpes zoster 29.9 HLA-A HLA-B IFNG IL10 IL2
42 monocytic leukemia 29.9 IFNG IL6 TNF
43 severe cutaneous adverse reaction 29.9 HLA-A HLA-B HLA-C TNF
44 measles 29.9 IFNG IL2 IL6
45 viral encephalitis 29.8 IL10 IL6 TNF
46 rubella 29.8 HLA-A HLA-B IL10 TNF
47 pericarditis 29.8 IFNG IL6 TNF
48 myasthenia gravis 29.8 CTLA4 IFNG IL10 IL2 TNF
49 pulmonary tuberculosis 29.8 IFNG IL10 IL2 TNF
50 central nervous system vasculitis 29.8 IFNG IL6 TNF

Graphical network of the top 20 diseases related to Hematopoietic Stem Cell Transplantation:



Diseases related to Hematopoietic Stem Cell Transplantation

Symptoms & Phenotypes for Hematopoietic Stem Cell Transplantation

GenomeRNAi Phenotypes related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

27 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.28 CLEC7A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.28 HLA-A HLA-B HLA-C CLEC7A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.28 CLEC7A
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.28 HLA-A HLA-B HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.28 HLA-E
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.28 HLA-A HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.28 CLEC7A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.28 HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.28 CLEC7A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.28 CLEC7A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.28 CLEC7A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.28 CLEC7A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.28 HLA-C HLA-E CLEC7A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.28 HLA-A HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.28 CLEC7A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.28 HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.28 CLEC7A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.28 HLA-E
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.28 HLA-A HLA-B HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.28 HLA-E CLEC7A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.28 HLA-A HLA-B HLA-C
22 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.28 HLA-C CLEC7A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.28 CLEC7A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.28 CLEC7A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.28 CLEC7A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.28 CLEC7A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.28 HLA-A HLA-B HLA-C HLA-E
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.28 HLA-C
29 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.28 CLEC7A
30 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.28 HLA-A HLA-B HLA-C
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.28 HLA-A HLA-B HLA-C
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.28 CLEC7A
33 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.28 CLEC7A
34 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.28 HLA-C

MGI Mouse Phenotypes related to Hematopoietic Stem Cell Transplantation:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CLEC7A CTLA4 IFNG IL10 IL2 IL6
2 liver/biliary system MP:0005370 9.5 CTLA4 IFNG IL10 IL2 IL6 MTHFR
3 respiratory system MP:0005388 9.17 CLEC7A CTLA4 IFNG IL10 IL2 IL6

Drugs & Therapeutics for Hematopoietic Stem Cell Transplantation

Drugs for Hematopoietic Stem Cell Transplantation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 637)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
2
Ferrous succinate Approved Phase 4 10030-90-7
3
Iron Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 7439-89-6, 15438-31-0 27284 23925
4
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
5
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
6
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 477468 3081921
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
8
Aprepitant Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 170729-80-3 6918365 151165
9
Fosaprepitant Approved Phase 4,Phase 1,Phase 2,Not Applicable 172673-20-0 219090
10
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
13
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
14
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179045-86-4, 152923-56-3
15
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
16
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2353-33-5 451668
17
Nystatin Approved, Vet_approved Phase 4,Phase 3 1400-61-9 11953884
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
19
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
20
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
21
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 6473866 445643 439492
22
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84625-61-6 55283
23
Lomustine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13010-47-4 3950
24
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
25
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
26
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
27
Vidarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
28
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
29
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
30
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
31
Foscarnet Approved Phase 4,Phase 3,Phase 2 4428-95-9, 63585-09-1 3415
32
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
33
Deferasirox Approved, Investigational Phase 4,Phase 2 201530-41-8 5493381
34
Protein C Approved Phase 4
35
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
36
Haloperidol Approved Phase 4 52-86-8 3559
37
inotuzumab ozogamicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 635715-01-4
38
Crizotinib Approved Phase 4,Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
41
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
42
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 50-14-6 5280793
43
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 1406-16-2
44
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 67-97-0 5280795 6221
45
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
46
Cobalamin Experimental Phase 4 13408-78-1 6857388
47
Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13909-09-6
48
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2 4408-78-0 546
49
Treosulfan Investigational Phase 4,Phase 3,Phase 2,Phase 1 299-75-2 9296
50 Epoetin alfa Phase 4,Phase 2,Phase 3 113427-24-0

Interventional clinical trials:

(show top 50) (show all 1972)
# Name Status NCT ID Phase Drugs
1 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
2 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
3 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
4 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
5 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
6 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
7 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
8 Oral Hygiene Regimen in Patients on HCT Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
9 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
10 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
11 Post Hematopoietic Stem Cell Transplantation Completed NCT01610297 Phase 4 ICL670
12 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
13 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
14 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
15 Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
16 Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients Completed NCT00204958 Phase 4 nutritional supplement;glutamine popsicle
17 Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload Completed NCT00654589 Phase 4 Deferasirox
18 Bronchodilator Responsiveness in Obliterative Bronchiolitis Completed NCT01112241 Phase 4 albuterol plus tiotropium
19 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
20 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
21 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
22 Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Completed NCT03489551 Phase 4 Haldol
23 Adjuvanted Influenza Vaccine in Stem Cell Transplant Completed NCT02560909 Phase 4
24 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
25 A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
26 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
27 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
28 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
29 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
30 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
31 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
32 Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Recruiting NCT03023631 Phase 4
33 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
34 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
35 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
36 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
37 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
38 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
39 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
40 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
41 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
42 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
43 Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation Unknown status NCT02313792 Phase 3 Palifermin
44 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
45 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3
46 Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML Unknown status NCT02474290 Phase 2, Phase 3 Sorafenib
47 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
48 MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT Unknown status NCT02673008 Phase 2, Phase 3
49 Allogeneic Transplantation For Severe Osteopetrosis Unknown status NCT00775931 Phase 2, Phase 3 Campath-1H;Cyclophosphamide;Busulfan;Fludarabine monophosphate
50 Lactobacillus Brevis CD2 Preventing Oral Mucositis Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2

Search NIH Clinical Center for Hematopoietic Stem Cell Transplantation

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Genetic Tests for Hematopoietic Stem Cell Transplantation

Anatomical Context for Hematopoietic Stem Cell Transplantation

MalaCards organs/tissues related to Hematopoietic Stem Cell Transplantation:

42
T Cells, Myeloid, Bone, Bone Marrow, B Cells, Lung, Kidney

Publications for Hematopoietic Stem Cell Transplantation

Articles related to Hematopoietic Stem Cell Transplantation:

(show top 50) (show all 4580)
# Title Authors Year
1
Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review. ( 30087462 )
2019
2
Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. ( 30038351 )
2019
3
Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30344086 )
2019
4
Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation. ( 30461314 )
2019
5
Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allogenic hematopoietic stem cell transplantation: a systematic approach. ( 30632829 )
2019
6
The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models. ( 30668984 )
2019
7
G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 30683906 )
2019
8
Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1303-1310]. ( 30953638 )
2019
9
Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 1939-1947]. ( 30954498 )
2019
10
Cytomegalovirus Retinitis in Children and Adolescents with Acute Leukemia following allogeneic Hematopoietic Stem Cell Transplantation. ( 30972869 )
2019
11
Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. ( 31004545 )
2019
12
Cord Haploidentical Non-In Vitro T Cell Depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse of Refractory Acute Leukemia. ( 30205230 )
2019
13
Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. ( 29656333 )
2019
14
Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. ( 30292747 )
2019
15
Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for adult cerebral X-linked adrenoleukodystrophy. ( 30746707 )
2019
16
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. ( 30171618 )
2019
17
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. ( 30773707 )
2019
18
Combination of bortezomib in the induction, conditioning and consolidation with autologous hematopoietic stem cell transplantation in patients with immunoglobulin light chain amyloidosis. ( 30652338 )
2019
19
Comparable Outcome with a Faster Engraftment of Optimized Haploidentical Hematopoietic Stem Cell Transplantation Compared with Transplantations from Other Donor Types in Pediatric Acquired Aplastic Anemia. ( 30639824 )
2019
20
Comparison of Outcomes of Frontline Immunosuppressive Therapy and Frontline Haploidentical Hematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anemia Who Lack an HLA-Matched Sibling Donor. ( 30658223 )
2019
21
Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia. ( 30900367 )
2019
22
Comparable Outcomes of First-Line Hematopoietic Stem Cell Transplantation from Unrelated and Matched Sibling Donors in Adult Patients with Aplastic Anemia: A Retrospective Single-Center Study. ( 30926448 )
2019
23
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. ( 30963471 )
2019
24
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party. ( 30328134 )
2019
25
A Case of Allergic Broncopulmonary Aspergillosis Associated With Hematopoietic Stem Cell Transplantation Due to Chronic Granulomatous Disease. ( 30095689 )
2019
26
Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation. ( 30700149 )
2019
27
Combination of pleuroparenchymal fibroelastosis with non-specific interstitial pneumonia and bronchiolitis obliterans as a complication of hematopoietic stem cell transplantation - Clues to a potential mechanism. ( 30792952 )
2019
28
Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. ( 30660643 )
2019
29
Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature. ( 30671909 )
2019
30
Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome. ( 30864116 )
2019
31
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. ( 30993415 )
2019
32
Quantitative Assessment of Liver Stiffness Using Ultrasound Shear Wave Elastography in Patients With Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Study. ( 30352484 )
2019
33
Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. ( 30391552 )
2019
34
Early Onset Granulomatous Colitis Associated with a Mutation in NCF4 Resolved with Hematopoietic Stem Cell Transplantation. ( 31027832 )
2019
35
Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation. ( 30972616 )
2019
36
Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post-allogeneic hematopoietic stem cell transplantation. ( 31054192 )
2019
37
Critical Role of Mismatched HLA in Hemorrhagic Cystitis after Haploidentical Hematopoietic Stem Cell Transplantation. ( 30735721 )
2019
38
Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation. ( 30681583 )
2019
39
The Effects of Fecal Donors with Different Feeding Patterns on Diarrhea in a Patient Undergoing Hematopoietic Stem Cell Transplantation. ( 31049232 )
2019
40
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. ( 30772906 )
2019
41
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. ( 29893798 )
2019
42
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation. ( 30996574 )
2019
43
Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein. ( 31050117 )
2019
44
Unrelated allogeneic hematopoietic stem cell transplantation in a patient with Revesz syndrome, a severe variant of dyskeratosis congenita. ( 30259646 )
2019
45
Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 30414316 )
2019
46
Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. ( 30316899 )
2019
47
Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. ( 30694451 )
2019
48
Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. ( 30710687 )
2019
49
Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319]. ( 30954497 )
2019
50
CD150highTreg cells may attenuate graft versus host disease and intestinal cell apoptosis after hematopoietic stem cell transplantation. ( 30972163 )
2019

Variations for Hematopoietic Stem Cell Transplantation

Expression for Hematopoietic Stem Cell Transplantation

Search GEO for disease gene expression data for Hematopoietic Stem Cell Transplantation.

Pathways for Hematopoietic Stem Cell Transplantation

Pathways related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 ARHGAP45 CLEC7A CTLA4 HLA-A HLA-B HLA-C
2
Show member pathways
13.45 CTLA4 HLA-A HLA-B HLA-C HLA-E KIR2DL1
3
Show member pathways
13.32 HLA-A HLA-B HLA-C HLA-E IFNG IL10
4
Show member pathways
13.05 IFNG IL10 IL2 IL6 TNF
5
Show member pathways
13 HLA-A HLA-B HLA-C HLA-E IL2 IL6
6
Show member pathways
12.97 HLA-A HLA-B HLA-C HLA-E IL6 TNF
7
Show member pathways
12.62 IFNG IL10 IL2 IL6 TNF
8
Show member pathways
12.61 IFNG IL10 IL2 IL6 TNF
9 12.59 CTLA4 IFNG IL10 IL2 TNF
10
Show member pathways
12.56 HLA-A HLA-B HLA-C HLA-E IFNG
11
Show member pathways
12.54 CTLA4 IFNG IL10 IL2 IL6 TNF
12
Show member pathways
12.46 HLA-A HLA-B HLA-C HLA-E
13 12.39 HLA-A HLA-B HLA-C HLA-E
14
Show member pathways
12.38 IFNG IL10 IL2 IL6
15
Show member pathways
12.37 IFNG IL2 IL6 MTHFR TNF
16 12.32 HLA-A HLA-B HLA-C HLA-E IL2 IL6
17 12.31 HLA-A HLA-B HLA-C HLA-E
18 12.27 CLEC7A IFNG IL10 IL6 TNF
19
Show member pathways
12.23 CLEC7A IL10 IL2 IL6 TNF
20
Show member pathways
12.18 CTLA4 HLA-A HLA-B HLA-C HLA-E IFNG
21 12.17 CLEC7A HLA-A HLA-B HLA-C HLA-E
22 12.13 CTLA4 HLA-A HLA-B HLA-C HLA-E
23
Show member pathways
12.13 HLA-A HLA-B HLA-C HLA-E IFNG IL2
24 12.07 HLA-A HLA-B HLA-C HLA-E IL6 KIR2DL1
25
Show member pathways
12.06 IFNG IL10 IL2 IL6 TNF
26
Show member pathways
12.04 IFNG IL10 IL2 IL6
27 12.03 IFNG IL2 IL6 TNF
28
Show member pathways
12.02 HLA-A HLA-B HLA-C HLA-E IFNG IL10
29
Show member pathways
12 IFNG IL6 TNF
30 12 IFNG IL10 IL2 IL6 TNF
31 11.95 IL10 IL6 TNF
32
Show member pathways
11.94 HLA-A IFNG IL2
33 11.93 IFNG IL10 IL6 TNF
34 11.93 HLA-A HLA-B HLA-C HLA-E KIR2DL1 KIR2DL3
35 11.9 IFNG IL10 IL2 IL6
36 11.9 CTLA4 IFNG IL6 TNF
37 11.84 IFNG IL10 IL2 TNF
38
Show member pathways
11.81 CTLA4 IFNG IL2 TNF
39 11.8 IFNG IL2 IL6
40 11.76 IL10 IL6 TNF
41 11.74 IFNG IL10 IL2 IL6 TNF
42
Show member pathways
11.71 IFNG IL2 IL6 TNF
43 11.71 IFNG IL10 IL2 IL6 TNF
44
Show member pathways
11.69 HLA-A IFNG IL2 TNF
45 11.59 IFNG IL2 IL6 TNF
46 11.57 IFNG IL10 IL6 TNF
47 11.56 IL10 IL6 TNF
48 11.55 IFNG IL2 TNF
49 11.53 IFNG IL10 IL2
50 11.52 IFNG IL6 TNF

GO Terms for Hematopoietic Stem Cell Transplantation

Cellular components related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 CTLA4 HLA-A HLA-B KIR2DL1 KIR2DL3 KIR3DL1
2 cell surface GO:0009986 9.85 HLA-A HLA-B HLA-C HLA-E TNF
3 early endosome membrane GO:0031901 9.67 HLA-A HLA-B HLA-C HLA-E
4 recycling endosome membrane GO:0055038 9.62 HLA-A HLA-B HLA-C HLA-E
5 phagocytic vesicle membrane GO:0030670 9.56 HLA-A HLA-B HLA-C HLA-E
6 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-A HLA-B HLA-C HLA-E
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-A HLA-B HLA-C HLA-E
8 MHC class I protein complex GO:0042612 8.92 HLA-A HLA-B HLA-C HLA-E
9 plasma membrane GO:0005886 10.17 ARHGAP45 CLEC7A CTLA4 HLA-A HLA-B HLA-C

Biological processes related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 IFNG IL10 IL2 IL6 TNF
2 adaptive immune response GO:0002250 9.93 CTLA4 HLA-E IFNG IL2
3 cytokine-mediated signaling pathway GO:0019221 9.93 IL10 IL2 IL6 TNF
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 IL10 IL6 TNF
5 defense response to Gram-positive bacterium GO:0050830 9.81 HLA-E IL6 TNF
6 type I interferon signaling pathway GO:0060337 9.81 HLA-A HLA-B HLA-C HLA-E
7 regulation of immune response GO:0050776 9.8 HLA-A HLA-B HLA-C HLA-E KIR2DL1 KIR2DL3
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 IFNG IL2 IL6
9 response to glucocorticoid GO:0051384 9.78 IL10 IL6 TNF
10 antigen processing and presentation GO:0019882 9.78 HLA-A HLA-B HLA-C HLA-E
11 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
12 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.73 HLA-A HLA-B HLA-C HLA-E
13 interferon-gamma-mediated signaling pathway GO:0060333 9.72 HLA-A HLA-B HLA-C HLA-E IFNG
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.71 HLA-A HLA-B HLA-C HLA-E
15 regulation of regulatory T cell differentiation GO:0045589 9.7 CTLA4 IFNG IL2
16 positive regulation of immunoglobulin secretion GO:0051024 9.67 HLA-E IL2 IL6
17 positive regulation of T cell mediated cytotoxicity GO:0001916 9.67 HLA-A HLA-B HLA-C HLA-E
18 positive regulation of glial cell proliferation GO:0060252 9.66 IL6 TNF
19 negative regulation of B cell proliferation GO:0030889 9.66 CTLA4 IL10
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
21 negative regulation of growth of symbiont in host GO:0044130 9.65 IL10 TNF
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
23 protection from natural killer cell mediated cytotoxicity GO:0042270 9.63 HLA-A HLA-B HLA-E
24 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
25 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
27 positive regulation of neuroinflammatory response GO:0150078 9.58 IL6 TNF
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 IFNG TNF
29 receptor biosynthetic process GO:0032800 9.56 IL10 TNF
30 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 IFNG TNF
31 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.46 HLA-A HLA-B HLA-C HLA-E
32 immune response GO:0006955 9.44 CTLA4 HLA-A HLA-B HLA-C HLA-E IFNG
33 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.26 HLA-A HLA-B HLA-C HLA-E
34 immune system process GO:0002376 10.02 CLEC7A CTLA4 HLA-A HLA-B HLA-C IL2

Molecular functions related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 IFNG IL10 IL2 IL6 TNF
2 beta-2-microglobulin binding GO:0030881 9.26 HLA-A HLA-E
3 peptide antigen binding GO:0042605 8.92 HLA-A HLA-B HLA-C HLA-E
4 protein binding GO:0005515 10.03 ARHGAP45 CLEC7A CTLA4 HLA-A HLA-B HLA-C

Sources for Hematopoietic Stem Cell Transplantation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....